|
Name |
Pentadecane
|
Molecular Formula | C15H32 | |
IUPAC Name* |
pentadecane
|
|
SMILES |
CCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C15H32/c1-3-5-7-9-11-13-15-14-12-10-8-6-4-2/h3-15H2,1-2H3
|
|
InChIKey |
YCOZIPAWZNQLMR-UHFFFAOYSA-N
|
|
Synonyms |
Pentadecane; N-PENTADECANE; 629-62-9; Pentadekan; Pentadecane, n-; CHEBI:28897; 16H6K2S8M2; CH3-[CH2]13-CH3; NSC-172781; n-Pentadecane 100 microg/mL in Acetonitrile; Pentadecane, analytical standard; HSDB 5729; EINECS 211-098-1; MFCD00008990; NSC 172781; BRN 1698194; pentadecan; dipentylfumarate; UNII-16H6K2S8M2; Medicinal Plant; 1-Penfadecane,(S); Pentadecane, >=99%; DSSTox_CID_7268; PENTADECANE [INCI]; EC 211-098-1; ghl.PD_Mitscher_leg0.43; DSSTox_RID_78379; DSSTox_GSID_27268; N-PENTADECANE [HSDB]; 4-01-00-00529 (Beilstein Handbook Reference); CH3(CH2)13CH3; CHEMBL1234557; DTXSID6027268; Pentadecane_Ramanathan &Gurudeeban; Pentadecane, >=98.0% (GC); ZINC1531089; Tox21_300535; LMFA11000006; NSC172781; STL280516; AKOS015902386; NCGC00164185-01; NCGC00164185-02; NCGC00254392-01; CAS-629-62-9; LS-14458; FT-0700536; P0606; C08388; D97801; Q150831; 896D4B7E-BF33-4D54-82CE-7360D88E8DC8
|
|
CAS | 629-62-9 | |
PubChem CID | 12391 | |
ChEMBL ID | CHEMBL1234557 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 212.41 | ALogp: | 7.7 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 12 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 15 | QED Weighted: | 0.341 |
Caco-2 Permeability: | -4.724 | MDCK Permeability: | 0.00000950 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.403 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.152 | Plasma Protein Binding (PPB): | 98.27% |
Volume Distribution (VD): | 3.726 | Fu: | 1.65% |
CYP1A2-inhibitor: | 0.413 | CYP1A2-substrate: | 0.199 |
CYP2C19-inhibitor: | 0.436 | CYP2C19-substrate: | 0.096 |
CYP2C9-inhibitor: | 0.127 | CYP2C9-substrate: | 0.943 |
CYP2D6-inhibitor: | 0.212 | CYP2D6-substrate: | 0.065 |
CYP3A4-inhibitor: | 0.195 | CYP3A4-substrate: | 0.053 |
Clearance (CL): | 4.637 | Half-life (T1/2): | 0.082 |
hERG Blockers: | 0.215 | Human Hepatotoxicity (H-HT): | 0.008 |
Drug-inuced Liver Injury (DILI): | 0.222 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.038 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.947 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.994 | Eye Irritation: | 0.943 |
Respiratory Toxicity: | 0.531 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000379 | 0.935 | D0Z5SM | 0.644 | ||||
ENC000422 | 0.930 | D07ILQ | 0.585 | ||||
ENC000427 | 0.878 | D05ATI | 0.552 | ||||
ENC000421 | 0.860 | D00AOJ | 0.528 | ||||
ENC000400 | 0.827 | D00FGR | 0.494 | ||||
ENC000739 | 0.792 | D0O1PH | 0.453 | ||||
ENC000272 | 0.791 | D0T9TJ | 0.410 | ||||
ENC000428 | 0.782 | D05QNO | 0.400 | ||||
ENC000281 | 0.750 | D0P1RL | 0.390 | ||||
ENC000425 | 0.745 | D00MLW | 0.380 |